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Neoadjuvant chemotherapy (NC) can improve the resectability of hepatic colorectal metastases (CRM). However, there is concern
regarding its impact on operative risk. We reviewed 750 consecutive liver resections performed for CRM in a single unit (1996–
2005) to evaluate whether NC affected morbidity and mortality. Redo hepatic resections or patients receiving adjuvant
chemotherapy following primary resection were excluded. A total of 245 resections were performed in patients not requiring NC
(control group) (mean age 63, 67% male) and 252 in patients who had NC (mean age 62, 67% male). The mean (s.d.) duration of
surgery was less in the control group (241(64) vs 255(64)min, P¼0.014) as was the mean blood loss (390(264) vs 449(424)ml,
P¼0.069). Postoperative mortality (2 vs 2%) and morbidity (27 vs 29%, P¼0.34) was similar between groups. More NC patients
developed septic (2.4%) or respiratory (10.3%) complications compared to controls (0 and 5.3%, Po0.03), with significantly more
surgical complications if the interval between stopping NC and undergoing surgery was p4 weeks (11%), compared to 5–8 (5.5%)
or 9–12 (2.6%) weeks (P¼0.009). The data suggest that liver resection for CRM is safe following NC. Early hepatobiliary
involvement in multidisciplinary cancer care may lead to avoidance of potential perioperative adverse events.
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Colorectal cancer is the third most common malignancy in the UK,
with an incidence of over 34000 (Cancer Research UK, 2006). Fifty
per cent of these patients will either present with or develop liver
metastases in the course of their disease (Scheele et al, 1990, 1995;
Sugarbaker, 1990; Stangl et al, 1994). Of these, 20–30% are suitable
for resection, which currently offers the greatest chance of cure,
with a 5-year survival after curative liver resection being 25–40%
(Hughes et al, 1986; Stangl et al, 1994; Scheele et al, 1995;
Nordlinger et al, 1996; Rees et al, 1997; Fong et al, 1999; Adam
et al, 2003).
Advances in surgical and anaesthetic technique have expanded
the indications for liver resection in the past 20 years. However, in
a landmark paper in 1996, Bismuth et al (1996) showed that
neoadjuvant chemotherapy (NC) could downstage liver meta-
stases. Their results demonstrated that 16% of previously
inoperable patients subsequently underwent liver resection with
curative intent and consequent 39% 5-year survival (Bismuth et al,
1996). This work, confirmed by others (Pozzo et al, 2004), has
resulted in NC now being more widely used to improve the
resectability of colorectal liver metastases. However, it is increas-
ingly clear that chemotherapy damages the hepatic parenchyma,
causing a chemotherapy-associated steatohepatitis (Fong and
Bentrem, 2006), which may adversely affect recovery after
hepatectomy (Elias et al, 1995; Pocard et al, 2001).
The aim of the study was to determine the impact of NC on
postoperative morbidity and mortality following liver resection for
colorectal metastases (CRM).
PATIENTS AND METHODS
The records of 750 consecutive patients undergoing liver resec-
tions for CRM with a curative intent in a single institution between
May 1997 and October 2005 were reviewed. Data were prospec-
tively recorded on an Access
s (Microsoft Corporation, Redmond,
WA, USA) database consisting of 268 data fields compiled
contemporaneously from a standardised proforma. Data validation
was performed by requesting duplicate information from patient
charts by a dedicated database officer. Details of the chemotherapy
regimens prospectively recorded included drug types, duration
of chemotherapy and the length of time (in weeks) between the
cessation of chemotherapy and liver resection. The time period
1997–2005 was chosen to include all patients given NC before liver
resection and a group of contemporaneous controls who had never
been exposed to chemotherapy. Patients undergoing resections
before May 1997 were excluded from the study to reduce potential
bias from improved surgical and anaesthetic technique (n¼179).
Those patients who had received neoadjuvant or adjuvant
chemotherapy prior or following resection of the primary tumour
(n¼181) and patients undergoing redo hepatic resections (n¼72)
were excluded from the study. The remaining 497 patients were
divided into two groups: a control group (n¼245) who had
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ssurgery alone and a chemotherapy group (n¼252) who received
NC before liver resection.
The indications for NC have evolved throughout the time period
of this study. Patients whose liver metastases were initially
unresectable would be offered NC in the hope of downstaging
their disease. Other potential indications for NC include patients
with advanced primary tumours, those presenting with synchro-
nous liver metastases, those with large or ill-located lesions close to
either portal or hepatic venous structures, patients with multiple,
bilobar metastases and patients with resectable extrahepatic
metastases. Moreover, the current UK guidelines (Garden et al,
2006) recommend that patients with resectable liver metastases
proceed straight to liver resection without NC. The definition of
resectable disease remained constant throughout the study period.
This was the ability to completely resect all liver metastases,
regardless of size, number, distribution or width of resection
margin, whereas preserving a sufficient volume of functioning
hepatic parenchyma (usually 25–30% of functioning liver volume
as estimated by computed tomography (CT) or magnetic
resonance imaging), portal venous and hepatic arterial inflow,
hepatic venous outflow and biliary drainage.
The anaesthetic and surgical techniques specific to hepatic
resection have been described in detail previously (Rees et al,
1996). All patients underwent liver resection using low-CVP
anaesthesia and intermittent inflow occlusion with the Pringle
clamp to reduce blood loss during the procedure. The standard
protocol used was repeated cycles of 20min inflow occlusion and
at least 5min of reperfusion, with the minimum amount of inflow
occlusion, ideally less than 60min. The parenchymal transection
was performed using the cavitron ultrasonic aspirator. Periopera-
tive pain relief entailed thoracic epidural analgesia and, more
recently, regional intermuscular bupivicaine infusion combined
with patient controlled-analgesia (Basu et al, 2004).
The study end points included intraoperative parameters
(duration of warm ischaemia and intraoperative blood loss) and
postoperative mortality and morbidity. Postoperative mortality
was defined as death during the same hospital admission or within
30 days of the operation date, if the patient was discharged earlier.
Postoperative complications were documented prospectively and
classified as minor, relevant (delayed patient discharge) or serious
(complications requiring urgent medical or surgical intervention).
The standard follow-up protocol included clinical examination,
estimation of serum carcinoembryonic antigen level and abdom-
inal ultrasonography or contrast-enhanced CT at 6 months, 1 year
and annually thereafter until death.
Statistical analysis
Continuous variables were compared using the analysis of variance
and categorical variables were analysed using the w
2 test or Fisher’s
Exact test as appropriate. Trends over time were assesses using the
w
2 test for trend (g-correction). P-values of o0.05 were considered
to represent statistical significance. Data were analysed using SPSS
software (version 11.0) (SPSS Inc., Chicago, IL, USA).
RESULTS
The patient demographics in the control and chemotherapy groups
are detailed in Table 1. Although the two groups were matched for
age and gender, there were significantly more patients with a clear
reduction in World Health Organisation performance status in the
chemotherapy group compared to the control group. In addition,
patients who received NC were more likely to have presented with
synchronous metastases and included a greater percentage of
patients with Dukes’ C primary disease. There was no difference in
the number or size of liver metastases between groups. The details
of the chemotherapy regimens in the chemotherapy group are
shown in Table 2. Over half of the patients received oxaliplatin-
based treatment. Table 3 shows the treatment intent of
chemotherapy, classified as irresectable/downsized or resectable
but given for other reasons, and the patients’ radiological
response, determined by CT scan.
The extent of liver resection performed was similar between the
control and NC groups (Table 4), but whereas the Pringle clamp
time was similar in both groups, the operating time was
significantly longer for the chemotherapy patients (P¼0.014) by
a means of 14min. In addition, the mean blood loss was higher
in the chemotherapy group (449ml) compared to the controls
(390ml), but this failed to reach statistical significance (P¼0.067).
Further examination of the largest subgroup of patients in the
chemotherapy group, the 127 patients (50.4%) who received
oxaliplatin-based chemotherapy was performed, with their opera-
tive details compared with those of the control patients. Again,
there was no difference in Pringle clamp time (19.8 vs 17.8min in
the controls, P¼0.12) and a significantly longer mean operating
Table 1 Patients’ demographic characteristics of patients undergoing
hepatic resection for colorectal liver metastasis with and without neo-
adjuvant chemotherapy; control group vs chemotherapy group
Control
(n¼245)
Chemotherapy
(n¼252) P-value
Age at liver surgery;
mean (s.d.) years
63 (10.8) 62 (9.8) 0.098
a
Male gender 163 (67%) 168 (67%) 1.0
b
Performance status;
n (%)
0.028
b
Normal/minimal
reduction
166 (67.8%) 149 (59.1%)
Clear reduction 79 (32.2%) 103 (40.9%)
Duke’s Stage of primary
tumour; n (%)
o0.001
b
Dukes’ A or B 145 (59.2%) 79 (31.3%)
Dukes’ C 99 (40.4%) 167 (66.3%)
Timing of liver
metastases; n (%)
o0.001
b
Synchronous 95 (38.8%) 151 (59.9%)
Metachronous 150 (61.2%) 101 (40.1%)
Number of liver
metastases; n (%)
0.26
b
1–3 211 (86.1%) 207 (82.1%)
43 33 (13.5%) 43 (17.1%)
Size of liver metastases;
n (%)
0.64
b
o5cm 164 (66.9%) 173 (68.2%)
45cm 81 (33.1%) 78 (31.0%)
s.d.¼standard deviation.
aANOVA.
bFisher’s Exact test.
Table 2 Chemotherapy agents
Drug(s) Number of resections (%)
Oxaliplatin+5-FUFA 127 (50.4)
5-FUFA or Capcitabine alone 55 (21.8)
Irinotecan75-FUFA 17 (6.7)
Mitomycin C+5-FUFA 9 (3.6)
Other 34 (13.5)
Not recorded 10 (4.0)
5-FUFA¼5-flurouracil/ folinic acid.
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stime (258 vs 241min in the controls, P¼0.012). However, in this
subgroup analysis, a significantly greater mean (s.d.) blood loss in
the patients receiving neoadjuvant oxaliplatin (473 (530) ml),
compared to the control patients (390 (264) ml, P¼0.046), was
shown.
There were 10-postoperative deaths in the series (2%), five in
each of the control and chemotherapy groups (P¼1.0, Fisher’s
Exact test). The cause of death is detailed in Table 5. Similarly,
there was no difference in overall morbidity, being 27% (66/245) in
the control and 29% (73/252) in the chemotherapy group (P¼0.34,
Fisher’s Exact test). The incidence of specific complications is
shown in Table 6. There were significantly more complications
from respiratory causes (P¼0.027) or sepsis/abscesses (P¼0.016)
in the chemotherapy group. The six cases complicated by sepsis/
abscess were two cases of sepsis/multiorgan failure, one epidural
abscess, that led to paraplegia, one patient with MRSA cellulitis,
one infected Hickman line and one patient who developed
peritonitis of unknown cause. There was no difference in the
incidence of hepatic insufficiency in the control (6.1%) or
chemotherapy (7.5%) groups (Table 6). This was minor (i.e. did
not delay discharge) in no patients in the control group and seven
in the chemotherapy group, significant (i.e. delayed discharge
beyond the 10th postoperative day) in 10 of the control and 10 of
the chemotherapy patients and significant requiring intervention
or admission to high-dependency or intensive therapy units in five
control and two chemotherapy patients. All of the seven patients in
this latter group underwent major hepatic resections. Of the five
patients in the control group, four developed infective complica-
tions (three pneumonia, one small bowel perforation related to
simultaneous closure of a loop ileostomy) and subsequent hepatic
insufficiency as a result of this ‘second hit’ and one patient
developed renal failure requiring haemofiltration, with hepatic
insufficiency. Of the two patients in the chemotherapy group, one
developed multiorgan failure including hepatic insufficiency
following a right hepaticectomy and the other patient had hepatic
insufficiency with infected ascites. One patient in each of the
control and chemotherapy groups received MARS liver support
therapy to treat their hepatic insufficiency (Steiner and Mitzner,
2002). One patient in each group died of multiorgan failure, on
19th (control patient) and 42nd postoperative day (chemotherapy
patient).
The time interval (in weeks) between finishing chemotherapy
and undergoing surgery (Figure 1) did not impact significantly on
postoperative morbidity (P¼0.96, w
2 test for trend). However,
Table 3 Treatment intent of and radiological (CT) response to
neoadjuvant chemotherapy
Response to neoadjuvant
chemotherapy
Resectable
(n¼161)
Inoperable, down
sized (n¼91)
No response/ stable disease (n)5 9 3
Partial response (n)9 1 8 7
Complete response (n)1 1 1
Table 4 Operative details
Control (n¼245) Chemotherapy (n¼252) P-value
Major resections (X3 segments); n (%) 144 (58.8) 153 (60.7) 0.36
a
Duration of surgery (min); mean (s.d.) 241.3 (64.2) 255.4 (63.6) 0.014
b
Duration pringle clamp (min); mean (s.d.) 17.8 (23.4) 21.4 (25.9) 0.19
b
Blood loss (ml); mean (s.d.) 390.4 (263.8) 448.8 (423.5) 0.067
b
s.d.¼standard deviation.
aFisher’s Exact test.
bANOVA.
Table 5 Cause of death in patients undergoing hepatic resection for
colorectal liver metastasis with (n¼252) and without (n¼245) neo-
adjuvant chemotherapy
Patient Cause of death
Control group
1 Chest Infection
2 Collapse at home – cause of death unknown
3 Sepsis/multiorgan failure
4 Multiorgan failure
5 Ischaemic colitis/haemorrhage/renal failure
Chemotherapy group
1 Sepsis/multiorgan failure
2 Peritonitis, cause unknown
3 Pneumonia/ARDS
4 Cardiac arrest 3rd postoperative day
5 Sepsis/multiorgan failure
ARDS¼acute respiratory distress syndrome.
Table 6 Specific postoperative complications in patients undergoing
hepatic resection for colorectal liver metastasis with (n¼252) and without
(n¼245) neoadjuvant chemotherapy
Control n (%) Chemotherapy n (%) P-value
a
Abscess/sepsis 0 6 (2.4) 0.016
Bile leak 3 (1.2) 2 (0.8) 0.487
Bleed 3 (1.2) 1 (0.4) 0.30
Cardiac 12 (4.9) 6 (2.4) 0.10
DVT/PE 3 (1.2) 7 (2.8) 0.18
Hepatic insufficiency 15 (6.1) 19 (7.5) 0.33
Respiratory 13 (5.3) 26 (10.3) 0.027
UTI 8 (3.3) 4 (1.6) 0.178
Wound infection 7 (2.9) 2 (0.8) 0.081
DVT¼deep vein thrombosis; PE¼pulmonary embolus; UTI¼urinary tract infection.
aFisher’s Exact test.
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Figure 1 The effect of timing of cessation of chemotherapy on
postoperative morbidity. *P¼0.96, w
2 test for trend.
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sFigure 2 illustrates the significant reduction in surgical complica-
tions with increasing time interval between the cessation of
chemotherapy and hepatic resection (P¼0.009).
The effect of the duration of chemotherapy on postoperative
morbidity and mortality was then considered. Patients were
grouped into those who had chemotherapy for less than 3 months,
3–6 months and more than 6 months (Table 7). Although there
appears to be a trend towards a higher incidence of life-threatening
and surgical complications if patients received more than 6
months of chemotherapy, this failed to reach statistical signifi-
cance. Similarly, there was a striking increase in postoperative
mortality (11%) in this group, but again this did not reach
statistical significance (Figure 3) possibly reflecting an insufficient
number of patients in this subgroup (n¼18) to generate adequate
statistical power.
DISCUSSION
Neoadjuvant chemotherapy has become an integral part of the
multidisciplinary management of metastatic colorectal cancer. It
can result in the downstaging of disease and thus improve hepatic
resection rates by 13–20% (Bismuth et al, 1996; Adam et al, 2001).
It can also provide an in vivo assessment of tumour chemorespon-
siveness, allowing clinicians to continue treatment for responders
or change treatment for nonresponders. Furthermore, there is
evidence that the response to chemotherapy is a prognostic
indicator of survival even when subsequent liver resection is
performed with curative intent (Allen et al, 2003; Adam et al,
2004). Lastly, for patients with synchronous disease or a short
disease-free interval, NC allows treatment of liver metastases and
systemic micrometastases simultaneously.
This study shows that NC before liver resection for CRM does
not increase postoperative morbidity and mortality. This finding is
supported by early data from the MD Anderson Cancer Centre on
108 patients who underwent major liver resection for CRM, of
whom 61 had preoperative chemotherapy (27 5-FUFA and 34 5-
FUFAþirinotecan) with no adverse effect on clinical outcome
(Parikh et al, 2003). A similar study from Belghiti’s group on 17
patients who had preoperative 5-FU, found no difference in
postoperative morbidity compared to 18 patients who received no
chemotherapy (Parc et al, 2000). These studies are in contrast to
the preliminary results of the EORTC multicentre trial of
preoperative chemotherapy (5-FUFAþoxaliplatin) and surgery
for resectable colorectal liver metastases vs surgery alone
(Nordlinger et al, 2005). Although the trial investigators also
found no difference in 30-day mortality between the two groups,
there was an increased incidence of postoperative complications in
the chemotherapy arm (24.5%) compared to the surgery alone arm
(13.3%). Transient liver failure (6.4 vs 1.6%), biliary fistula (5.5 vs
1.6%) and intra-abdominal infections (4.5 vs 0.8%) were all higher
in those patients who had received NC compared to those
undergoing surgery alone. Karoui et al (2006) have recently
published a study examining the effects of preoperative che-
motherapy on postoperative morbidity and mortality in 67
patients who underwent major hepatectomy under total vascular
exclusion. These patients were particularly at risk of postoperative
complications owing to the extent and complexity of the surgery.
They showed that in this high-risk group, the 45 patients who had
preoperative chemotherapy had significantly more postoperative
complications (38%) compared with those who did not have
chemotherapy (13.5%, P¼0.03). Although the present results
showed a higher incidence of hepatic insufficiency in those
patients who had NC, this difference failed to reach statistical
significance, possibly reflecting the low overall incidence of this
complication in this series. A significant increase in respiratory
and septic complications in the patients receiving NC, compared to
the controls was, however, demonstrated.
There is some evidence that NC results in increased hepatic
steatosis, which can impair postoperative liver regeneration and
lead to hepatic insufficiency. The present study did not specifically
assess the resected specimens for evidence of steatosis, unlike the
MD Anderson study, which found an increased incidence of
steatosis in those patients who had had preoperative chemother-
apy, most marked in those who had received irinotecan. This is
supported by work from Steve Strasberg’s group, who evaluated
liver biopsies of patients referred for resection of colorectal liver
metastases. They found a significantly increased incidence of
nonalcoholic steatohepatitis in those patients who had received
neoadjuvant oxalipliatin or irinotecan, compared to patients who
had 5-FU alone or those who did not have chemotherapy before
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Figure 2 The effect of timing of cessation of chemotherapy on surgical
complications. *P¼0.009, w
2 test for trend.
Table 7 Effect of the duration of chemotherapy on morbidity and
mortality n¼(%) following hepatic resection for colorectal liver metastasis
Duration of chemotherapy
Control o3m 3–6m 46m
Outcome n¼245 n¼13 n¼216 n¼18 P-value*
Any morbidity 66 (27%) 4 (31%) 61 (28%) 7 (39%) 0.487
Life-threatening complications13 (5%) 0 (0%) 11 (5%) 3 (17%) 0.438
Medical complications 53 (22%) 4 (31%) 55 (26%) 4 (22%) 0.373
Surgical complications 22 (9%) 0 (0%) 9 (4%) 3 (17%) 0.230
Mortality 5 (2%) 0 (0%) 3 (1%) 2 (11%) 0.645
w
2 test for trend. In n¼5 (2%) patients the duration of chemotherapy was not
recorded.
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Figure 3 Effect of the duration of chemotherapy on postoperative
mortality. *P¼0.65, w
2 test for trend.
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sliver resection (Fernandez et al, 2005). However, is there any
evidence that steatosis affects clinical outcome? Pocard et al (2001)
found that chemotherapy-induced steatosis impaired postopera-
tive hepatic regeneration in patients undergoing hepatectomy for
breast cancer metastases. Moreover, Didolkar et al (1989) showed
that patients receiving preoperative chemotherapy had minimal
liver regeneration on postoperative CT scanning and that these
patients were more likely to develop postoperative hepatic
insufficiency. A more recent paper from MD Anderson examined
the histological changes associated with preoperative chemother-
apy and correlated them with postoperative outcome after liver
resection for CRM. Not only did they confirm their earlier findings
that irinotecan was associated with a steatohepatitis, but they also
found that patients with steatohepatitis had a significantly higher
90-day mortality (14.7%) compared to patients who did not have
steatohepatitis (1.6%) (Vauthey et al, 2006). Others have
investigated the effect of steatosis per se on clinical outcome
following liver resection, finding that patients with steatosis had
increased morbidity (Belghiti et al, 2000) and were more likely to
have had preoperative chemotherapy and had more postoperative
complications compared to controls with no steatosis (Kooby et al,
2003). A further histological study of the resected liver specimens
following oxaliplatin-based NC has revealed a distinct pattern of
liver injury. In 80% of the specimens, the authors found striking
dilatation and rupture of the hepatic sinusoids, with progression to
perisinusoidal and veno-occlusive fibrosis (Rubbia-Brandt et al,
2004). This finding of hepatic sinusoidal dilatation associated with
oxaliplatin therapy has also been confirmed by others, but not
proven to adversely affect outcome (Vauthey et al, 2006). It may
however underlie our own clinical experience, and that of others,
that the postchemotherapy liver parenchyma can be stiff and more
liable to bleed during transection. This is reflected by our findings
of significantly increased blood loss in those patients receiving
oxaliplatin-based NC compared to the control patients and a
significantly longer duration of surgery in all the chemotherapy
patients compared to the controls.
The present data demonstrate how the postoperative morbidity,
life-threatening complications and surgical complications were
all greater in the small number of patients (n¼18) who had
chemotherapy for more than 6 months duration. These differences
failed to reach statistical significance, possibly due to the small
numbers involved (a Type II error). This is in contrast to an
analysis of our early experience (1987–2002) where we found
significantly increased morbidity in those patients who had had
chemotherapy for more than 6 months (Basu et al, 2003). This led
to our current practice of delaying surgery until the patient has
recovered from any side effects associated with chemotherapy,
such as bone marrow suppression and when their general fitness is
optimised. Despite this patient-centred approach, the performance
status in the chemotherapy patients was still significantly reduced
compared to the controls, before liver resection. There is little
published evidence regarding the impact of dose or duration of
preoperative chemotherapy on postoperative morbidity following
liver resection for CRM. One study from Germany on 30 patients
who underwent either three or six cycles of preoperative
oxaliplatin-based chemotherapy (FOLFOX regimen) found no
difference in postoperative outcome between the two regimens
(Lorenz et al, 2003). Indeed, in (Bismuth et al, 1996) landmark
paper on downstaging chemotherapy (using an oxaliplatin-based
regimen), the mean duration of chemotherapy needed to confer
operability was approximately 8 months (Bismuth et al, 1996) and
yet the consequent morbidity (26%) and mortality (zero) were low.
However, the recent paper from Nordlinger’s group, examining
high-risk patients undergoing major hepatectomy under total
vascular exclusion, reported a positive correlation between post-
operative morbidity and the number of cycles of preoperative
chemotherapy (Karoui et al, 2006).
In this study, hepatic resection was performed in 12 patients
who had had a complete response to chemotherapy. The authors
believe it is important to resect all documented sites of disease
within the liver, even if some lesions have shown a complete
response to chemotherapy, as there is evidence that these
metastases will eventually recur. Benoist et al (2006) prospectively
followed 38 patients who had multiple colorectal liver metastases
and who received NC before hepatic resection. They found that 55
out of 66 metastases (83%) that had shown a complete radiological
response to chemotherapy had either residual (macroscopic or
microscopic) disease at operation, or recurrent disease at a year.
In conclusion, this is the largest study to date, which has
addressed the question as to whether NC increases the risk of liver
resection for CRM. The present study confirmed that chemother-
apy before resection of colorectal liver metastases is safe, despite
the performance status of the patients receiving chemotherapy
being lower than that of the controls, and the surgery taking
longer, with more associated blood loss. However, whereas NC has
become an integral part of the quest to improve resection rates
and survival, no treatment is without risk, as highlighted by the
increased respiratory and septic complications in the chemo-
therapy group. The present study suggests that avoiding giving
chemotherapy for a prolonged duration and carefully timing
subsequent liver surgery to each individual patient’s recovery from
chemotherapy may result in immediate outcomes comparable to
those patients who have not received chemotherapy. We would
advocate the involvement of hepatobiliary surgeons at an early
stage in the multidisciplinary management of these patients,
allowing appropriate planning of surgical and chemotherapeutic
strategies.
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